Coloplast A/S (OTCMKTS:CLPBY) & PROCEPT BioRobotics (NASDAQ:PRCT) Head-To-Head Review

PROCEPT BioRobotics (NASDAQ:PRCT) and Coloplast A/S (OTCMKTS:CLPBY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for PROCEPT BioRobotics and Coloplast A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2	9	2	3	2.38
Coloplast A/S	1	1	0	1	2.33

PROCEPT BioRobotics presently has a consensus price target of $25.50, indicating a potential upside of 35.49%. Given PROCEPT BioRobotics’ stronger consensus rating and higher possible upside, equities analysts clearly believe PROCEPT BioRobotics is more favorable than Coloplast A/S.

Profitability

This table compares PROCEPT BioRobotics and Coloplast A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-32.53%	-30.62%	-22.10%
Coloplast A/S	9.68%	39.27%	11.54%

Valuation & Earnings

This table compares PROCEPT BioRobotics and Coloplast A/S”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$308.05 million	3.50	-$95.57 million	($1.94)	-9.70
Coloplast A/S	$4.13 billion	3.92	$538.49 million	$0.19	37.84

Coloplast A/S has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

PROCEPT BioRobotics has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.21, suggesting that its share price is 79% less volatile than the S&P 500.

Institutional & Insider Ownership

89.5% of PROCEPT BioRobotics shares are held by institutional investors. 4.0% of PROCEPT BioRobotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.